search
Back to results

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM) (B to B)

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
INSULIN GLARGINE
INSULIN GLULISINE
Insulin aspart
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  1. Sub-optimally controlled Type 2 Diabetes Mellitus (T2DM) patients treated with insulin glargine for a minimum of 3 months:

    • Sub-optimal: HbA1c level >7% and fasting blood glucose <130mg/dL
  2. Male or Female ≥18 years old
  3. Body Mass Index (BMI) <40
  4. 10% ≥HbA1c ≥7%
  5. If taking Oral anti-diabetics (OADs), must be on stable dose for at least 1 months
  6. Patients willing to sign data release consent form

Exclusion criteria:

  1. Diabetes other than T2DM
  2. Enrolled in other clinical trials
  3. Previous treatment with an insulin other than insulin glargine
  4. Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or with Di Peptidyl Peptidase 4 (DPP-IV) inhibitors
  5. Pregnant or lactating women
  6. Contraindicated to Lantus (insulin glargine) / Apidra (insulin glulisine) / Novomix 30 (insulin aspart)
  7. Treatment with systemic corticoid steroids within the last 3 months prior to study enter
  8. Treatment with any investigational product within the last 3 months prior to study entry

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

  • Administrative Office

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

group 1: Basal plus

group 2: Biphasic insulin

Arm Description

Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)

Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).

Outcomes

Primary Outcome Measures

Change in hemoglobin A1c level (HbA1c)

Secondary Outcome Measures

Rate of hypoglycemic events (total, severe, nocturnal)
Proportion of patients with HbA1c < 7%
Change in body weight
Reactive Oxidative Stress (ROS) level changes
Change in Quality of Life
Continuous Glucose Monitoring System (CGMS) data

Full Information

First Posted
September 30, 2010
Last Updated
July 5, 2013
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT01212913
Brief Title
Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)
Acronym
B to B
Official Title
Comparison of a Basal Plus (Insulin Glargine/Insulin Glulisine) Regimen to Biphasic Insulin (InsulinAspart/Insulin Aspart Protamine 30/70) in T2DM Patients Who Require Insulin Intensification After Basal Insulin Optimization.
Study Type
Interventional

2. Study Status

Record Verification Date
July 2013
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
May 2012 (Actual)
Study Completion Date
May 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Primary Objective: To demonstrate the non-inferiority of hemoglobin A1c (HbA1c) control at six months between the basal plus one and the biphasic insulin regimen. Secondary Objective: To demonstrate favorable outcome for basal plus over biphasic insulin when it comes to comparing when both hemoglobin A1c (HbA1c) target goal achievement and non-hypoglycemic event is taken into account.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
161 (Actual)

8. Arms, Groups, and Interventions

Arm Title
group 1: Basal plus
Arm Type
Experimental
Arm Description
Insulin glargine with dosage adjustment determined according to the mean value of the last three days Fasting Blood Glucose (FBG) Insulin glulisine, at initial dosing of 4IU, then weekly adjusted according to the mean value of the last three days PostPrandial Blood Glucose (PPBG)
Arm Title
group 2: Biphasic insulin
Arm Type
Active Comparator
Arm Description
Insulin aspart/insulin aspart protamine 30/70 (novomix 30) given twice daily and titrated weekly (before breakfast and dinner) according to the lowest of three previous days' pre-meal levels (both breakfast and dinner). Target is 70 mg/dL < Pre-meal blood glucose (dinner and breakfast).
Intervention Type
Drug
Intervention Name(s)
INSULIN GLARGINE
Other Intervention Name(s)
Lantus
Intervention Description
Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
Intervention Type
Drug
Intervention Name(s)
INSULIN GLULISINE
Other Intervention Name(s)
Apidra
Intervention Description
Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
Intervention Type
Drug
Intervention Name(s)
Insulin aspart
Other Intervention Name(s)
NovoMix 30
Intervention Description
Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
Primary Outcome Measure Information:
Title
Change in hemoglobin A1c level (HbA1c)
Time Frame
At 6 months of treatment
Secondary Outcome Measure Information:
Title
Rate of hypoglycemic events (total, severe, nocturnal)
Time Frame
from baseline to the study endpoint (over 6 months of treatment)
Title
Proportion of patients with HbA1c < 7%
Time Frame
from baseline to the study endpoint (over 6 months of treatment)
Title
Change in body weight
Time Frame
from baseline to the study endpoint (over 6 months of treatment)
Title
Reactive Oxidative Stress (ROS) level changes
Time Frame
from baseline to the study endpoint (over 6 months of treatment)
Title
Change in Quality of Life
Time Frame
from baseline to the study endpoint (over 6 months of treatment)
Title
Continuous Glucose Monitoring System (CGMS) data
Time Frame
at baseline, 3 and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Sub-optimally controlled Type 2 Diabetes Mellitus (T2DM) patients treated with insulin glargine for a minimum of 3 months: Sub-optimal: HbA1c level >7% and fasting blood glucose <130mg/dL Male or Female ≥18 years old Body Mass Index (BMI) <40 10% ≥HbA1c ≥7% If taking Oral anti-diabetics (OADs), must be on stable dose for at least 1 months Patients willing to sign data release consent form Exclusion criteria: Diabetes other than T2DM Enrolled in other clinical trials Previous treatment with an insulin other than insulin glargine Treatment with Glucagon-like peptide-1 (GLP-1) receptor agonists or with Di Peptidyl Peptidase 4 (DPP-IV) inhibitors Pregnant or lactating women Contraindicated to Lantus (insulin glargine) / Apidra (insulin glulisine) / Novomix 30 (insulin aspart) Treatment with systemic corticoid steroids within the last 3 months prior to study enter Treatment with any investigational product within the last 3 months prior to study entry The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Administrative Office
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
25952532
Citation
Jin SM, Kim JH, Min KW, Lee JH, Ahn KJ, Park JH, Jang HC, Park SW, Lee KW, Won KC, Kim YI, Chung CH, Park TS, Lee JH, Lee MK. Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial. J Diabetes. 2016 May;8(3):405-13. doi: 10.1111/1753-0407.12312. Epub 2015 Jun 29.
Results Reference
derived

Learn more about this trial

Comparison of Insulin Glargine/Insulin Glulisine Regimen to Insulin Aspart/Insulin Aspart Protamine 30/70 in Type 2 Diabetes Mellitus Patients (T2DM)

We'll reach out to this number within 24 hrs